MAPT and Alzheimer disease: Interestingly, neuroparin is reported to attenuate the abnormal tau immunoreactivity (representative of an AD-related conformational alteration of tau) in rat hippocampus following unilateral injection of Aβ25-35 into the amygdala (Dudas et al., 2002).